|View printer-friendly version|
|Array BioPharma Forms Chemistry-Based Research Agreement with Lilly for Drug Discovery|
|BOULDER, Colo.—(March 28, 2000)—Array BioPharma Inc. today announced that it has signed an agreement with Eli Lilly and Company to form a chemistry-based research collaboration. Under the agreement, up to 30 Array scientists will work in collaboration with Lilly scientists on several drug discovery projects. |
"We are excited that Lilly has chosen to collaborate with Array as a means of expanding its drug discovery capabilities," said Robert E. Conway, Chief Executive Officer of Array BioPharma Inc. "This agreement reflects an emerging trend in which leading pharmaceutical companies are outsourcing certain medicinal chemistry needs with selective collaborations. This agreement is also a milestone for Array which validates our approach to providing both innovative products and drug discovery chemistry services."
Array BioPharma Inc., based in Boulder, Colorado, is a privately held discovery research organization (DRO™) comprised of leading chemists. The company provides innovative products and research services in all aspects of chemistry, high-throughput screening, structural biology and information management. Array BioPharma is at the forefront of translating genomic discoveries into safe and effective therapeutics. For additional information, visit the company’s web site at www.arraybiopharma.com.
David Snitman, Ph.D.